202 related articles for article (PubMed ID: 32133282)
1. CT-Based Radiomic Signature as a Prognostic Factor in Stage IV
Li H; Zhang R; Wang S; Fang M; Zhu Y; Hu Z; Dong D; Shi J; Tian J
Front Oncol; 2020; 10():57. PubMed ID: 32133282
[No Abstract] [Full Text] [Related]
2. Assessment of a Radiomic Signature Developed in a General NSCLC Cohort for Predicting Overall Survival of ALK-Positive Patients With Different Treatment Types.
Huang L; Chen J; Hu W; Xu X; Liu D; Wen J; Lu J; Cao J; Zhang J; Gu Y; Wang J; Fan M
Clin Lung Cancer; 2019 Nov; 20(6):e638-e651. PubMed ID: 31375452
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
4. MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer.
Zhao S; Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Ding L; Mao L; Wu N
Transl Lung Cancer Res; 2021 Jan; 10(1):368-380. PubMed ID: 33569319
[TBL] [Abstract][Full Text] [Related]
5. Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.
Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Zhang Z; Ding L; Wu N; Zhao S
Thorac Cancer; 2021 Sep; 12(17):2388-2399. PubMed ID: 34288491
[TBL] [Abstract][Full Text] [Related]
6. Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With
Tang X; Li Y; Yan WF; Qian WL; Pang T; Gong YL; Yang ZG
Front Oncol; 2021; 11():719919. PubMed ID: 34660285
[TBL] [Abstract][Full Text] [Related]
7. A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts ALK Rearrangement Status in Lung Adenocarcinoma.
Chang C; Sun X; Wang G; Yu H; Zhao W; Ge Y; Duan S; Qian X; Wang R; Lei B; Wang L; Liu L; Ruan M; Yan H; Liu C; Chen J; Xie W
Front Oncol; 2021; 11():603882. PubMed ID: 33738250
[TBL] [Abstract][Full Text] [Related]
8. A radiomics prognostic scoring system for predicting progression-free survival in patients with stage IV non-small cell lung cancer treated with platinum-based chemotherapy.
He L; Li Z; Chen X; Huang Y; Yan L; Liang C; Liu Z
Chin J Cancer Res; 2021 Oct; 33(5):592-605. PubMed ID: 34815633
[TBL] [Abstract][Full Text] [Related]
9. Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer.
Jain P; Khorrami M; Gupta A; Rajiah P; Bera K; Viswanathan VS; Fu P; Dowlati A; Madabhushi A
Front Oncol; 2021; 11():744724. PubMed ID: 34745966
[TBL] [Abstract][Full Text] [Related]
10. Predicting anaplastic lymphoma kinase rearrangement status in patients with non-small cell lung cancer using a machine learning algorithm that combines clinical features and CT images.
Hao P; Deng BY; Huang CT; Xu J; Zhou F; Liu ZX; Zhou W; Xu YK
Front Oncol; 2022; 12():994285. PubMed ID: 36338735
[TBL] [Abstract][Full Text] [Related]
11. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
[TBL] [Abstract][Full Text] [Related]
12. Identification of Stage IIIC/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model.
Shao D; Du D; Liu H; Lv J; Cheng Y; Zhang H; Lv W; Wang S; Lu L
Front Oncol; 2021; 11():721318. PubMed ID: 34796106
[TBL] [Abstract][Full Text] [Related]
13. Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.
de Jong EEC; van Elmpt W; Rizzo S; Colarieti A; Spitaleri G; Leijenaar RTH; Jochems A; Hendriks LEL; Troost EGC; Reymen B; Dingemans AC; Lambin P
Lung Cancer; 2018 Oct; 124():6-11. PubMed ID: 30268481
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Wu Y; Nordstrom B; Socinski MA
Oncologist; 2020 Oct; 25(10):867-877. PubMed ID: 32490560
[TBL] [Abstract][Full Text] [Related]
15. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
16. Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors.
Wang TW; Chao HS; Chiu HY; Lu CF; Liao CY; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Transl Oncol; 2024 Jan; 39():101826. PubMed ID: 37984256
[TBL] [Abstract][Full Text] [Related]
17. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC.
Fan Y; Wang X; Dong Y; Cui E; Wang H; Sun X; Su J; Luo Y; Yu T; Jiang X
Eur Radiol; 2023 Nov; 33(11):7902-7912. PubMed ID: 37142868
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer.
Zhang L; Chen B; Liu X; Song J; Fang M; Hu C; Dong D; Li W; Tian J
Transl Oncol; 2018 Feb; 11(1):94-101. PubMed ID: 29216508
[TBL] [Abstract][Full Text] [Related]
19. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
20. Radiomic-signature changes after early treatment improve the prediction of progression-free survival in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Zhang Z; Ding L; Wu N; Zhao S
Acta Radiol; 2023 Mar; 64(3):1194-1204. PubMed ID: 35971221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
